EXEL News and Press, Exelixis Inc. From 01/04/22

– Veteran drug developer’s career spans patient care, the FDA and biopharma – – Dr. Goodman will lead Exelixis’ expansion to the East Coast – Exelixis, Inc. (Nasdaq: EXEL) today announced the appointment of Vicki ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips “Buy low, sell high” is the mantra for success in the investing world. Consequently, investors are always looking for opportunities to scoop up cheap stocks that could offer incredible value over the long run....

The growing demand for efficient and viable drugs, vaccines, and treatments for curing chronic diseases and newly emerging coronavirus variants should accelerate the biotech industry’s growth over the long term. Thus, it might be wise to invest in undervalued biotech stocks Regeneron (...

-- Ms. Wright has decades of private and public sector technology experience including time at Microsoft, BP, General Electric and the UK government -- Exelixis, Inc. (Nasdaq: EXEL) today announced that accomplished technology executive Jacqueline (Jacky) Wright has ...

Exelixis (NASDAQ:EXEL) announces initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating XL092 in combination with immuno-oncology therapies in advanced solid tumors. The objective of the study is to evaluate the safety, tolerability and efficacy of XL092, in combi...

– STELLAR-002 is second trial to evaluate XL092, a next-generation tyrosine kinase inhibitor, in advanced cancers – Exelixis, Inc. (Nasdaq: EXEL) today announced initiation of the dose-escalation stage of STELLAR-002, a phase 1b trial evaluating XL092 i...

One way to gauge how much potential a stock has is by looking at the price targets analysts set for it. Normally they're for a period of two years or less, but they can change depending on a company's results. And there are two stocks that, if they hit their price targets, could double with...

Although the Healthcare sector is having a positive year in absolute terms, that isn't the case in relative terms. Biotech stocks are having a difficult year, in spite of many of those trading at dirt-cheap valuations that don't even reflect the cash they have in-hand. It's very l...

Since the last earnings report, shares of Exelixis declined over 20% because of a slight adjustment of the FJ outlook. Total revenue is still likely to grow 35% in FJ 2021 at the midpoint of the updated guidance. The company continues to expand the Cabometxy label with further ind...

– Global, phase 3 pivotal trial part of ongoing clinical collaboration with Roche – Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is now completed for CONTACT-01, the global, phase 3 pivotal trial evaluating cabozantinib (CABOMETYX ® ...